Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, double-blind, parallel group, phase 3 trial
- Resource Type
- Article
- Source
- The Lancet Diabetes & Endocrinology; March 2023, Vol. 11 Issue: 3 p169-181, 13p
- Subject
- Language
- ISSN
- 22138587; 22138595